| 1 (95) | Hypertension Arterielle, Pulmonaire: Physiopathologie et Innovation Therapeutique | FRA |  |
| 2 (100) | Genentech Inc | USA | |
| 3 (103) | Sanofi, United States | USA | |
| 4 (111) | Hoffmann-La Roche Ltd, United States | USA | |
| 5 (160) | Bristol-Myers Squibb Company, United States | USA | |
| 6 (181) | AstraZeneca, United States | USA | |
| 7 (210) | GlaxoSmithKline, United States | USA | |
| 8 (248) | Merck & Co Inc, United States | USA | |
| 9 (250) | Boehringer Ingelheim GmbH Germany | DEU | |
| 10 (290) | Eli Lilly and Company, United States | USA | |
| 11 (297) | GlaxoSmithKline, United Kingdom | GBR | |
| 12 (310) | Regeneron Pharmaceuticals Inc * | USA | |
| 13 (340) | AstraZeneca, Sweden | SWE | |
| 14 (459) | AstraZeneca, United Kingdom | GBR | |
| 15 (489) | Bayer AG, Germany | DEU | |
| 16 (537) | Sanofi, France | FRA | |
| 17 (572) | Analysis Group Inc | USA | |
| 18 (662) | Novartis, Switzerland | CHE | |
| 19 (762) | Boehringer Ingelheim, USA | USA | |
| 20 (833) | Bosch, Germany | DEU | |
| 21 (1352) | Takeda Pharmaceuticals International Inc, USA | USA | |
| 22 (1365) | Pharmaceutical Product Development LLC | USA | |
|
